Memic Innovative Surgery, a medical device company with headquarters in Israel and Florida, received FDA authorization to introduce the first of its kind robotic surgical system that utilizes humanoid-shaped arms to achieve impressive reach and procedural safety. It is intended for benign hysterectomies or the removal of the uterus for non-cancerous conditions along with the removal of one or both fallopian tubes and ovaries.
The humanoid-shaped arms provide human-level dexterity, multi-planar flexibility, and 360 degrees of movement. The biomimetic designs are meant to replicate the motions and capabilities of a surgeon’s arms, with shoulder, elbow, and wrist joints.
The Hominis system “offers a small, cost-effective and less invasive option over current robotic instruments limited to the straight shaft and single wrist designs and controlled with large, complex, and expensive equipment. This authorization is also just the beginning; it opens the door for our novel system to expand to additional indications that, until now, have been off-limits to robot-assisted surgery. – Dvir Cohen, CEO of Memic.
Hysteroscopy Procedure Numbers
Over 460,000 hysterectomy procedures are performed annually in the US. The trans-vaginal approach – as opposed to abdominal hysterectomies – has been shown as resulting in better clinical benefits, including less patient pain and scarring, shorter recovery times, and reduced infection rates. However surgeons rarely use the trans-vaginal approach due to anatomical barriers and accessibility challenges.
Register to receive a free US Market Report Suite for Minimally Invasive Surgery (MIS) Robotic Devices 2020 – 2026 synopsis
The main driver behind the hysteroscopy procedure numbers is the growing elderly population. Many conditions that require hysteroscopy are more evident in the older female demographics. Moreover, hysteroscopy plays a large part in fertility assistance, as it can be used in the determination of uterine abnormalities. It has also been suggested that the hysteroscopic removal of fibroid and polyps improves the success rates of in vitro fertilization (IVF). As couples are increasingly opting to undergo IVF procedures and to obtain fertility assistance, it is expected that hysteroscopy procedures will also grow.
Minimally Invasive Surgery Robotic Device Market Size
In 2020, the minimally invasive surgery (MIS) robotic device market was valued at over $3.3 billion. The market includes the capital equipment segment, the LUA segment, and the service and maintenance revenue segment. The MIS robotic device market is projected to grow at an annual rate of over 11% to reach nearly $6 billion by 2025. This impressive growth will largely be fueled by the recurring revenue generated from each procedure performed with robotic systems.